Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion type Assertion NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_head.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion description "[The frequency of particular forms of LGMD2 was 32.6% for LGMD2A (71 probands), 4.1% for LGMD2I (9 probands), 2.8% for LGMD2D (6 probands), and 1.4% for LGMD2L (3 probands).Further, we present the first results of a new approach established in the Czech Republic for diagnosis of neuromuscular diseases: sequence capture and targeted resequencing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_provenance.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion evidence source_evidence_literature NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_provenance.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion SIO_000772 25135358 NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_provenance.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion wasDerivedFrom befree-20150227 NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_provenance.
- NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_assertion wasGeneratedBy ECO_0000203 NP980086.RA4UDLPG1HAWZZH-KlmoHrDXtALiBd7_Nl0U_GR_NG5vE130_provenance.